The level of OCT3/SLC22A3 expression has also been linked to the level of patient responsiveness towards cancer treatments20; in particular, platin-based cytotoxic cancer treatments in colorectal cancer21 patients, as well as head and neck squamous cell carcinoma patients18. This evidence concerns the gene SLC22A3 and cancer.